Bio-Rad LaboratoriesFRA:BUWA +1.48%72 Days Payable is 42.04 as of Mar. 2026, which is 3% above its 10-year median of 40.97. GuruFocus rates FRA:BUWA with a GF Score™ of 72/100 and a GF Value™ of €272.77 (Fairly Valued). The stock has 5 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Bio-Rad Laboratories ranks worse than 76.86% on this metric.
The historical rank and industry rank for Bio-Rad Laboratories's Days Payable or its related term are showing as below:
FRA:BUWA'
s Days Payable Range Over the Past 10 Years
Min: 36.89 Med: 40.97 Max: 52.26
Current: 39.12
During the past 13 years, Bio-Rad Laboratories's highest Days Payable was 52.26. The lowest was 36.89. And the median was 40.97.
FRA:BUWA's Days Payable is ranked worse than 76.86% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs FRA:BUWA: 39.12
Bio-Rad Laboratories's Days Payable
declined
from Mar. 2025 (43.14) to Mar. 2026 (42.04).
It may suggest that Bio-Rad Laboratoriesaccelerated paying its suppliers.
Bio-Rad Laboratories Days Payable Related Terms
Bio-Rad Laboratories Days Payable Historical Data
* Premium members only.
The historical data trend for Bio-Rad Laboratories's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:BUWA vs GKOS, BRKR, PODD: Days Payable Comparison
For the Medical Devices subindustry, Bio-Rad Laboratories's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Rad Laboratories Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's Days Payable distribution charts can be found below:
* The bar in red indicates where Bio-Rad Laboratories's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Bio-Rad Laboratories's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Rad Laboratories (FRA:BUWA) has a Days Payable of 42.04 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Bio-Rad Laboratories and its competitors. This is near median its historical median of 40.97. Over the past decade, Bio-Rad Laboratories' Days Payable has ranged from 36.89 to 52.26. According to the industry distribution chart, Bio-Rad Laboratories ranks #611 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 76.9%.
Is Bio-Rad Laboratories' Days Payable too high?
Bio-Rad Laboratories' current Days Payable of 42.04 is near median its 10-year median of 40.97. Over the past 10 years, this metric has ranged from a low of 36.89 to a high of 52.26. The Medical Devices & Instruments industry median Days Payable is 68.07. Bio-Rad Laboratories' value of 42.04 is 38.2% below this industry median. Based on the distribution chart, Bio-Rad Laboratories ranks #611 out of 795 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Bio-Rad Laboratories has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bio-Rad Laboratories' Days Payable compare to GKOS and BRKR?
According to the Medical Devices & Instruments industry distribution chart, Bio-Rad Laboratories ranks #611 out of 795 companies for Days Payable. This places Bio-Rad Laboratories in the lower half of its industry. The industry median Days Payable is 68.07. Bio-Rad Laboratories' value of 42.04 is 38.2% below this benchmark. Historically, Bio-Rad Laboratories' own Days Payable has ranged from 36.89 to 52.26 over the past decade. While the company's 10-year median is 40.97 vs. the industry median of 68.07, Bio-Rad Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio-Rad Laboratories's current Days Payable of 42.04 is 38.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Bio-Rad Laboratories and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Rad Laboratories's current Days Payable is 42.04, which is near median its own 10-year median of 40.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Rad Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Bio-Rad Laboratories (FRA:BUWA) is currently considered Fairly Valued. The stock's GF Value™ is €272.77, compared to a current price of €260.40 — trading 4.5% below its estimated fair value. The current Days Payable is 42.04, which is near median its 10-year median of 40.97 and 38.2% below the Medical Devices & Instruments industry median of 68.07. Bio-Rad Laboratories' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Bio-Rad Laboratories (FRA:BUWA), the current Days Payable is 42.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Rad Laboratories (FRA:BUWA) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Rad Laboratories stock appears to be undervalued.
The current stock price of €260.40 is trading 4.5% below its estimated GF Value™ of €272.77.
GuruFocus considers Bio-Rad Laboratories to be Fairly Valued.
Key valuation signals for FRA:BUWA:
Days Payable: 42.04 (near median its 10-year median of 40.97)
GF Value™: €272.77 vs. price of €260.40 (4.5% below fair value)
Industry Position: 38.2% below the Medical Devices & Instruments median (#611 of 795)
No single metric tells the full story. See the FRA:BUWA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
72GF Score
Get the complete analysis for FRA:BUWA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BUWA has been successfully added to your 
